Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05078723 · ClinicalTrials.gov registry record · NA
CYP2C19 Variants and Limonene Metabolism
A NA study of CYP2C19 Genetic Variants, sponsored by Stanford University.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05078723: Recruiting NA study of CYP2C19 Genetic Variants, sponsored by Stanford University.
NCT05078723 is a NA study of CYP2C19 Genetic Variants that is actively recruiting participants, run by Stanford University. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05078723, a NA study of CYP2C19 Genetic Variants, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will examine whether a non-invasive screening tool for CYP2C19 genetic variants can be developed by measuring limonene metabolism.
Primary Outcome
The amount of limonene in the breath will be measured by mass spectrometry for each participant.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Limonene
Study Locations (1)
California
- Stanford School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-10-30 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT05078723 shows while recruiting
NCT05078723 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with CYP2C19 Genetic Variants appearing as the primary indexed condition, and to 1 intervention - of which Limonene is the first listed.
NCT05078723 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05078723 about?
NCT05078723 is a clinical study titled "CYP2C19 Variants and Limonene Metabolism". The investigators will examine whether a non-invasive screening tool for CYP2C19 genetic variants can be developed by measuring limonene metabolism.
What is the current status of trial NCT05078723?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2021-10-30. Estimated completion is 2026-12.
What conditions does trial NCT05078723 study?
This clinical trial studies the following conditions: CYP2C19 Genetic Variants.
What interventions are being tested in trial NCT05078723?
The interventions under investigation include: Limonene (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05078723?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05078723 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05078723's enrollment target sits among peer trials
20 1769th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI